Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AG-707 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AG-707 | DRUG | - |
Inclusion Criteria: * Patients must be seropositive for HSV-2 (+/- HSV-1) and have a documented history of clinically active genital herpes (at least one prior outbreak). * Patients must be seronegative for HIV. * Patients must be seronegative for hepatitis B and C * Have baseline chemistry and hem...
AG-707 is an investigational therapy being developed for genital herpes, a sexually transmitted infection caused by herpes simplex virus type 2. It is a small molecule designed to stimulate an immune response against the virus. Agenus Inc. is evaluating it in clinical development, and it has not been approved for commercial use.
AG-707 targets HSV-2 antigens, which are proteins from the herpes simplex virus type 2. By presenting these antigens, the therapy aims to elicit an immune response against the virus. This antigen-based approach is intended to help the body recognize and combat HSV-2, the virus responsible for genital herpes.
AG-707 is being developed by Agenus Inc., a biotechnology company traded on the Nasdaq under the ticker symbol AGEN. Agenus focuses on immuno-oncology and infectious disease therapies. The company has advanced AG-707 into clinical testing for genital herpes.
AG-707 is in Phase 1 clinical development. It has completed a Phase 1 trial evaluating its safety, tolerability, and immune response in patients with genital herpes. As an investigational product, it has not received FDA approval and remains in the early stages of clinical research.
AG-707 has been studied in a completed Phase 1 trial, NCT00231049, titled "Trial Evaluating Safety, Tolerability and Immune Response of AG-707." The trial enrolled 35 participants with genital herpes in the United States. It was randomized but uncontrolled and not double-blind, and it has finished.